Aastrom Biosciences Announces First Patient Enrolled in REVIVE Phase 3 ...
Review seeker (press release) - May 10, 2012
Review seeker (press release) - May 10, 2012
By Globenewswire ANN ARBOR, Mich., May 9, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, ...
View the full article